Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

597 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.
Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E. Wheeler CM, et al. Among authors: dillner j. J Infect Dis. 2009 Apr 1;199(7):936-44. doi: 10.1086/597309. J Infect Dis. 2009. PMID: 19236277 Clinical Trial.
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E. Brown DR, et al. Among authors: dillner j. J Infect Dis. 2009 Apr 1;199(7):926-35. doi: 10.1086/597307. J Infect Dis. 2009. PMID: 19236279 Clinical Trial.
EUROGIN 2008 roadmap on cervical cancer prevention.
Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM. Franceschi S, et al. Among authors: dillner j. Int J Cancer. 2009 Nov 15;125(10):2246-55. doi: 10.1002/ijc.24634. Int J Cancer. 2009. PMID: 19521965 Free article. Review.
Prospective study of human papillomavirus and risk of cervical adenocarcinoma.
Dahlström LA, Ylitalo N, Sundström K, Palmgren J, Ploner A, Eloranta S, Sanjeevi CB, Andersson S, Rohan T, Dillner J, Adami HO, Sparén P. Dahlström LA, et al. Among authors: dillner j. Int J Cancer. 2010 Oct 15;127(8):1923-30. doi: 10.1002/ijc.25408. Int J Cancer. 2010. PMID: 20473898 Free PMC article.
Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix.
Sundström K, Eloranta S, Sparén P, Arnheim Dahlström L, Gunnell A, Lindgren A, Palmgren J, Ploner A, Sanjeevi CB, Melbye M, Dillner J, Adami HO, Ylitalo N. Sundström K, et al. Among authors: dillner j. Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2469-78. doi: 10.1158/1055-9965.EPI-10-0424. Epub 2010 Jul 29. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20671136 Free PMC article.
Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer.
Arnheim Dahlström L, Andersson K, Luostarinen T, Thoresen S, Ögmundsdottír H, Tryggvadottír L, Wiklund F, Skare GB, Eklund C, Sjölin K, Jellum E, Koskela P, Wadell G, Lehtinen M, Dillner J. Arnheim Dahlström L, et al. Among authors: dillner j. Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2541-50. doi: 10.1158/1055-9965.EPI-11-0761. Epub 2011 Oct 12. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21994401
597 results